CDK4/6抑制剂在HR阳性/HER2阴性乳腺癌新辅助治疗中的研究进展

Research progress in CDK4/6 inhibitors in neoadjuvant therapy of HRpositive HER2-negative breast cancer

细胞周期蛋白依赖性激酶(cyclin-dependent kinase,CDK)4/6抑制剂是一类新型靶向治疗药物,通过抑制细胞周期的进展来阻断恶性肿瘤细胞的增殖。目前,CDK4/6抑制剂在激素受体阳性(hormone receptor positive,HR+)/人表皮生长因子受体2阴性(human epidermal growth factor receptor 2 negative,HER2-)晚期或转移性乳腺癌患者的治疗中已取得了成功的应用。研究表明,CDK4/6抑制剂联合内分泌治疗可显著延长晚期乳腺癌患者的无进展生存期,并且耐受性良好。然而,CDK4/6抑制剂在早期乳腺癌患者中的疗效尚无定论。近年来,许多临床试验开始探讨CDK4/6抑制剂在早期HR+/HER2-乳腺癌新辅助治疗中的应用前景。本文对CDK4/6抑制剂新辅助治疗HR+/HER2-乳腺癌新的临床试验最新进展进行综述,以期为提高这类患者的病理完全缓解(pathologic complete response,pCR)率以及改善其预后提供参考依据。

Cyclin-dependent kinase(CDK)4/6 inhibitors are a new class of targeted therapeutics that block the proliferation of malignant tumor cells by inhibiting the progression of cell cycle.CDK4/6 inhibitors have been successfully used in patients with hormone receptor positive(HR+)/human epidermal growth factor receptor 2 negative(HER2-)advanced or metastatic breast cancer.CDK4/6 inhibitors combined with endocrine therapy significantly extended progressionfree survival in patients with advanced stage and were well tolerated.However,its efficacy in patients with early breast cancer has not been determined.In recent years,many clinical trials have begun to explore the application prospect of CDK4/6 inhibitors in neoadjuvant therapy of early HR+/HER2-breast cancer.In this paper,the latest clinical trials of neoadjuvant therapy with CDK4/6 inhibitors in order to improve pathologic complete response(pCR)rate and prognosis of patients with HR+/HER2-breast cancer were reviewed.